Javascript must be enabled to continue!
e0071 Effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats
View through CrossRef
Objective
To investigate effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats.
Methods
24 male SD rats were randomly divided into three groups: normal control (n=8), untreated and STZ-induced diabetic rats (n=8) and diabetic rats treated with fluvastatin (n=8). DM was induced in male SD rats with a single intraperitoneal (i.p.) injection of streptozotocin 50 mg/kg dissolved in 20 mM citrate buffer (pH 4.5) overnight. Tail vein blood glucose was measured 72 h later and those with plasma glucose levels ≥16.7 mmol/l were considered to be diabetic. Control rats were injected 1 ml/kg body weight of 20 mM citrate buffer (pH 4.5) vehicle, and diabetic rats were treated with fluvastatin (10 mg/kg administered orally, n=8). Fluvastatin were dissolved in sterile water, and administered every day via stomach tube. These rats were housed for 12 weeks with daily general checking. After 12 weeks intervention, miniature cardiac catheter was inserted into the left ventricle to conduct haemodynamic examination. Then, myocardium tissues were collected, collagen content was detected by picro-sirius red staining, immunohistochemistry was used to detect protein expression of fibronectin, real-time RT-PCR was used to detect the mRNA expression of CTGF and Western blotting was used to detect the protein expression of CTGF. RhoA activity in LV myocardial tissue of rats was determined by pull down assay.
Results
By the end of the experiment, the left ventricular systolic pressure (LVSP)(97±12 mm Hg vs 131±21 mm Hg) and maximum rate of left ventricular (LV) pressure rise and fall (+dP/dt max and -dP/dt max) (4410±332 mm Hg/s vs 6465±442 mm Hg/s and −4326±365 mm Hg/s vs-6432±426 mm Hg/s) were significantly lower and left ventricular end diastolic pressure (LVEDP)(16.2±3.2 mm Hg vs 4.8±1.2 mm Hg) were significantly higher in the diabetic group compared to the control group (all p<0.01). Moreover, in LV myocardial tissue of diabetic rats the collagen content (4.2%±0.36% vs 6.4%±0.33%, p<0.01), fibronectin (3.12±0.30 vs 0.95±0.33, p<0.01), mRNA and protein expression of CTGF (0.86±0.10 vs 1.37±0.24 and 0.48±0.13 vs 1.26±0.22, p<0.01) and the activity of RhoA (1.72±0.21 vs 1.1±0.1, p<0.01) were all significantly increased compared to the control rats. Administration of fluvastatin obviously improved the cardiac function of diabetic rats, attenuated fibronectin expression, mRNA and protein expression of CTGF and the activity of RhoA in LV myocardium of diabetic rats.
Conclusions
Our data demonstrate that fluvastatin attenuates cardiac dysfunction and myocardial interstitial fibrosis of diabetic rat by inhibiting activity of RhoA to down-regulate the over-expression of CTGF, and Rho/Rho-kinase pathway may be an important target in the treatment of diabetic cardiomyopathy.
Title: e0071 Effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats
Description:
Objective
To investigate effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats.
Methods
24 male SD rats were randomly divided into three groups: normal control (n=8), untreated and STZ-induced diabetic rats (n=8) and diabetic rats treated with fluvastatin (n=8).
DM was induced in male SD rats with a single intraperitoneal (i.
p.
) injection of streptozotocin 50 mg/kg dissolved in 20 mM citrate buffer (pH 4.
5) overnight.
Tail vein blood glucose was measured 72 h later and those with plasma glucose levels ≥16.
7 mmol/l were considered to be diabetic.
Control rats were injected 1 ml/kg body weight of 20 mM citrate buffer (pH 4.
5) vehicle, and diabetic rats were treated with fluvastatin (10 mg/kg administered orally, n=8).
Fluvastatin were dissolved in sterile water, and administered every day via stomach tube.
These rats were housed for 12 weeks with daily general checking.
After 12 weeks intervention, miniature cardiac catheter was inserted into the left ventricle to conduct haemodynamic examination.
Then, myocardium tissues were collected, collagen content was detected by picro-sirius red staining, immunohistochemistry was used to detect protein expression of fibronectin, real-time RT-PCR was used to detect the mRNA expression of CTGF and Western blotting was used to detect the protein expression of CTGF.
RhoA activity in LV myocardial tissue of rats was determined by pull down assay.
Results
By the end of the experiment, the left ventricular systolic pressure (LVSP)(97±12 mm Hg vs 131±21 mm Hg) and maximum rate of left ventricular (LV) pressure rise and fall (+dP/dt max and -dP/dt max) (4410±332 mm Hg/s vs 6465±442 mm Hg/s and −4326±365 mm Hg/s vs-6432±426 mm Hg/s) were significantly lower and left ventricular end diastolic pressure (LVEDP)(16.
2±3.
2 mm Hg vs 4.
8±1.
2 mm Hg) were significantly higher in the diabetic group compared to the control group (all p<0.
01).
Moreover, in LV myocardial tissue of diabetic rats the collagen content (4.
2%±0.
36% vs 6.
4%±0.
33%, p<0.
01), fibronectin (3.
12±0.
30 vs 0.
95±0.
33, p<0.
01), mRNA and protein expression of CTGF (0.
86±0.
10 vs 1.
37±0.
24 and 0.
48±0.
13 vs 1.
26±0.
22, p<0.
01) and the activity of RhoA (1.
72±0.
21 vs 1.
1±0.
1, p<0.
01) were all significantly increased compared to the control rats.
Administration of fluvastatin obviously improved the cardiac function of diabetic rats, attenuated fibronectin expression, mRNA and protein expression of CTGF and the activity of RhoA in LV myocardium of diabetic rats.
Conclusions
Our data demonstrate that fluvastatin attenuates cardiac dysfunction and myocardial interstitial fibrosis of diabetic rat by inhibiting activity of RhoA to down-regulate the over-expression of CTGF, and Rho/Rho-kinase pathway may be an important target in the treatment of diabetic cardiomyopathy.
Related Results
PROTECTIVE EFFECTS OF ERYTHROPOIETIN ON CARDIAC FUNCTION IN DIABETIC RATS
PROTECTIVE EFFECTS OF ERYTHROPOIETIN ON CARDIAC FUNCTION IN DIABETIC RATS
Objectives
To investigate the protective effects of erythropoietin on cardiac function of diabetic rats and its mechanism
...
MICRORNAS CONTROL CARDIAC FIBROSIS
MICRORNAS CONTROL CARDIAC FIBROSIS
Objectives
Cardiac fibrosis is characterised by aberrant proliferation of cardiac fibroblasts and exaggerated deposition of extracellular matrix (ECM) in the myoc...
Fluvastatin-mediated suppression of IgE-induced cytokine production can be enhanced by TGFβ1 (HYP3P.403)
Fluvastatin-mediated suppression of IgE-induced cytokine production can be enhanced by TGFβ1 (HYP3P.403)
Abstract
Fluvastatin, an HMG-CoA reductase inhibitor known for its role in the treatment of hypercholesterolemia and cardiovascular disease, has recently been shown ...
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
Abstract
Cardiac fibrosis leads to decreased cardiac compliance, impaired systolic and diastolic function, resulting in heart failure. M6A methylation plays a role in fibro...
The lncRNA Sros1 is involved in the development of cardiac fibrosis by regulating the TGF-β/SMAD2/3 signaling cascade
The lncRNA Sros1 is involved in the development of cardiac fibrosis by regulating the TGF-β/SMAD2/3 signaling cascade
Abstract
Aim: Myocardial fibrosis is one of the common pathophysiological mechanisms of heart failure (HF) caused by various etiologies. Interferon (IFN)-γ plays a key role...
Adiponectin Modified BMSCs Alleviate Heart Fibrosis via Inhibition TGF-beta1/Smad in Diabetic Rats
Adiponectin Modified BMSCs Alleviate Heart Fibrosis via Inhibition TGF-beta1/Smad in Diabetic Rats
Background: Accumulating evidence suggested that bone marrow mesenchymal stem cells (BMSCs) have therapeutic potential for diabetes and heart diseases. However, the effects of BMSC...
Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis
Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis
Abstract:
Cardiac fibrosis is considered as unbalanced extracellular matrix production and degradation, contributing to heart failure. Short-chain acyl-CoA dehydrogenase ...
DJ-1 overexpression restores ischaemic post-conditioning-mediated cardioprotection in diabetic rats: role of autophagy
DJ-1 overexpression restores ischaemic post-conditioning-mediated cardioprotection in diabetic rats: role of autophagy
IPO (ischaemic post-conditioning) is a promising method of alleviating myocardial IR (ischaemia-reperfusion) injury; however, IPO-mediated cardioprotection is lost in diabetic hear...


